These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30961642)

  • 1. Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs.
    Lin T; Ren Q; Zuo W; Jia R; Xie L; Lin R; Zhao H; Chen J; Lei Y; Wang P; Dong H; Huang L; Cai J; Peng Y; Yu Z; Tan J; Wang S
    J Exp Clin Cancer Res; 2019 Apr; 38(1):150. PubMed ID: 30961642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.
    Ciardiello C; Roca MS; Noto A; Bruzzese F; Moccia T; Vitagliano C; Di Gennaro E; Ciliberto G; Roscilli G; Aurisicchio L; Marra E; Mancini R; Budillon A; Leone A
    Oncotarget; 2016 Apr; 7(15):19559-74. PubMed ID: 26862736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paeoniflorin Potentiates the Inhibitory Effects of Erlotinib in Pancreatic Cancer Cell Lines by Reducing ErbB3 Phosphorylation.
    Hao J; Yang X; Ding XL; Guo LM; Zhu CH; Ji W; Zhou T; Wu XZ
    Sci Rep; 2016 Sep; 6():32809. PubMed ID: 27609096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
    Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D
    Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valproic acid induces NET cell growth arrest and enhances tumor suppression of the receptor-targeted peptide-drug conjugate via activating somatostatin receptor type II.
    Sun L; Qian Q; Sun G; Mackey LV; Fuselier JA; Coy DH; Yu CY
    J Drug Target; 2016; 24(2):169-77. PubMed ID: 26211366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
    Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B
    Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.
    Contessa JN; Abell A; Mikkelsen RB; Valerie K; Schmidt-Ullrich RK
    Breast Cancer Res Treat; 2006 Jan; 95(1):17-27. PubMed ID: 16267617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells.
    Gilardini Montani MS; Granato M; Santoni C; Del Porto P; Merendino N; D'Orazi G; Faggioni A; Cirone M
    Cell Oncol (Dordr); 2017 Apr; 40(2):167-180. PubMed ID: 28160167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zinc finger transcription factors designed for bispecific coregulation of ErbB2 and ErbB3 receptors: insights into ErbB receptor biology.
    Lund CV; Popkov M; Magnenat L; Barbas CF
    Mol Cell Biol; 2005 Oct; 25(20):9082-91. PubMed ID: 16199884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flotillin depletion affects ErbB protein levels in different human breast cancer cells.
    Asp N; Pust S; Sandvig K
    Biochim Biophys Acta; 2014 Sep; 1843(9):1987-96. PubMed ID: 24747692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesenchymal stem cells drive paclitaxel resistance in ErbB2/ErbB3-coexpressing breast cancer cells via paracrine of neuregulin 1.
    Chen J; Ren Q; Cai Y; Lin T; Zuo W; Wang J; Lin R; Zhu L; Wang P; Dong H; Zhao H; Huang L; Fu Y; Yang S; Tan J; Lan X; Wang S
    Biochem Biophys Res Commun; 2018 Jun; 501(1):212-219. PubMed ID: 29715459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
    Wang S; Huang X; Lee CK; Liu B
    Oncogene; 2010 Jul; 29(29):4225-36. PubMed ID: 20498641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.
    Chen X; Yeung TK; Wang Z
    Biochem Biophys Res Commun; 2000 Nov; 277(3):757-63. PubMed ID: 11062025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
    Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL
    Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
    Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD
    Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-296-5p suppresses EMT of hepatocellular carcinoma via attenuating NRG1/ERBB2/ERBB3 signaling.
    Shi DM; Li LX; Bian XY; Shi XJ; Lu LL; Zhou HX; Pan TJ; Zhou J; Fan J; Wu WZ
    J Exp Clin Cancer Res; 2018 Nov; 37(1):294. PubMed ID: 30486894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
    Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F
    Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
    Alvarado D; Ligon GF; Lillquist JS; Seibel SB; Wallweber G; Neumeister VM; Rimm DL; McMahon G; LaVallee TM
    PLoS One; 2017; 12(7):e0181356. PubMed ID: 28723928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.